Trevena Stock News

-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

OLINVYK, oliceridine, is Trevena's first approved drug and offers a compelling safety, efficacy, and economic profile versus IV morphine.

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2021 Results - Earnings Call Transcript

The stock price of Trevena Inc (NASDAQ: TRVN) increased 2.82% (from $1.77 to $1.82) pre-market. This is why it happened.

-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS

Trevena: Taking A Systematic Approach With A Speculative Investment

The stock price of Trevena Inc (NASDAQ: TRVN) increased by over 5% pre-market. This is why it happened.

-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19

The stock price of Trevena Inc (NASDAQ: TRVN) has increased by over 30% pre-market. This is why it happened.

-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

These high-risk, high-reward healthcare stocks have outperformed the market over the past year.

Trevena (TRVN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q4 2020 Results - Earnings Call Transcript

-- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET